Navigation Links
CT Corsearch Announces Trademark Search Capabilities for the U.S. Pharmaceutical Market
Date:3/15/2010

ceutical trademark search combines key components in the clearance process that cover both standard trademark clearance and name safety components. The result is a big step forward in pharmaceutical clearance that incorporates the FDA's Phonetic Orthographic Computer Analysis (POCA) and summarizes unwieldy name safety data like Adverse Event Reporting System (AERS), Vaccine Adverse Event Reporting System (VAERS) into an easy-to-review summary format and overall, synthesizes name safety into the clearance process.

"Branding is a complex and potentially game-changing task for the pharmaceutical industry, where a particular name can generate millions and even billions of dollars in annual sales," said Stephen Anderson, manager of content development for CT Corsearch.  "Our new pharmaceutical trademark search addresses the two-pronged search capabilities required to help these companies be successful in clearing compelling brand names and identities quickly and effectively, so that they can focus on the task of bringing their products to market."

Key features of CT Corsearch's pharmaceutical search include:

  • A jurisdictional overview, summarizing where marks are cited across jurisdictions in chart form;
  • Funct
    '/>"/>

SOURCE CT Corsearch
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Decision Resources ... multiple sclerosis (MS) patients currently treated with ... have ever experienced flushing and/or gastrointestinal events ... patients are currently experiencing these side effects, ... effective medical management of such events. In ...
(Date:7/22/2014)... 2014 Research and Markets  has announced ... report to their offering. ... to diagnose, monitor, and assess medical conditions, diseases, or ... outcomes for earlier and more targeted treatment. These tests ... accurate results. This kind of diagnostics provides early detection ...
(Date:7/22/2014)... July 22, 2014  Eyeon Therapeutics has received a ... based on a charged hydrophilic polymer developed at Particles ... been shown to be safe and effective in a ... CEO states, "This first set of claims around the ... to moving this technology into the commercial phase.  We ...
Breaking Medicine Technology:Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
... MonoSol Rx, the developers of PharmFilm® technology and ... film products, today announced that it held a ... Food and Drug Administration (FDA) regarding the development ... a 505(b)(2) pathway.  The registration dossier of Montelukast ...
... 2011 PTC Therapeutics, Inc. (PTC) today announced the ... Medical Officer.  Dr. Spiegel served previously as Chief Medical ... of Jay Barth, M.D. to Vice President of Clinical ... Spiegel will report to Stuart W. Peltz, Ph.D., President ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3
(Date:7/22/2014)... Plate Club you eat pretty much everything you put ... Cornell University study shows that the average adult eats 92% ... plate. "If you put it on your plate, ... of the forthcoming book, Slim by Design, Professor of Marketing ... Wansink and co-author Katherine Abowd Johnson analyzed 1179 diners and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Legislation ... Seniors Access to Local Pharmacies Act of 2014”) ... Part D would undermine the availability of lower ... by $21 billion over the next 10 years, ... released by the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... New Rochelle, NY -- New guidelines on cholesterol treatment ... least double the risk of dying from atherosclerotic cardiovascular ... as do women with a similar risk profile (based ... levels). The implications of this finding for when and ... an Editorial in Journal of Men,s Health , ...
(Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
(Date:7/22/2014)... News) -- One of the largest studies ever conducted ... uncovered 83 new sites on chromosomes that harbor inherited ... an international team of researchers, now bring the total ... to 108. Although these schizophrenia-associated genes aren,t ... predict who will or will not develop the illness, ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... Edward G.,Rendell today issued an executive order regarding ... closed after the law,authorizing its operation expired on ... 2003, when PHC4 was allowed to "sunset",by the ... action., The Rendell administration is committed to ...
... Illinois at Chicago is one of 11 centers in ... in the Clinical Islet Transplant Consortium funded by the ... clinical studies to test new approaches to islet transplantation ... effects for adults with difficult-to-control type 1 diabetes. , ...
... to vote soon on legislation that would cut ... WASHINGTON, July 8 Seniors across,Pennsylvania are speaking ... in legislation being considered in the U.S. Senate. ... the Medicare Advantage,program in Pennsylvania alone and severely ...
... DETROIT, July 8 The Barbara Ann Karmanos,Cancer ... with Meadowbrook C,Management, LLC, to lease space and ... Michigan. The approximately 14,000 square foot,space will allow ... in Novi,and the surrounding communities, as well as ...
... cancer research, particularly in observational epidemiology studies. The ... mitigated if researchers use more exacting standards when ... in the July 8 online issue of the ... Additionally, the impact of false-positive results could be ...
... in Iron Blood Levels Associated with Decreased Cancer Risk in ... arterial disease who participated in a randomized controlled trial in ... a reduced incidence of cancer relative to men in the ... have suggested that lower levels of iron in the blood ...
Cached Medicine News:Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:Pennsylvania Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services 2Health News:Awareness of epidemiology's limitations could reduce impact of false-positive cancer results 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4
For the quantitative in vitro determination of Transferrin in Serum...
Determination of Reptilase Time.Extracted venom of Bothrops atrox. 20 BU (Batroxobin unit) per vial....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: